Repligen (NASDAQ:RGEN) Trading 10.3% Higher – What’s Next?

Repligen Corporation (NASDAQ:RGEN)’s share price was up 10.3% during mid-day trading on Thursday . The company traded as high as $124.37 and last traded at $124.7720. Approximately 586,495 shares traded hands during trading, a decline of 39% from the average daily volume of 955,606 shares. The stock had previously closed at $113.17.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on RGEN shares. Wells Fargo & Company lowered their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Barclays upped their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Roth Mkm initiated coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price objective for the company. Finally, Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $166.15.

Repligen Stock Up 1.0%

The company has a market capitalization of $6.99 billion, a PE ratio of 137.72, a price-to-earnings-growth ratio of 2.37 and a beta of 1.09. The company’s fifty day moving average is $117.94 and its 200-day moving average is $139.78. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $194.26 million for the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts predict that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several large investors have recently made changes to their positions in RGEN. Measured Wealth Private Client Group LLC purchased a new stake in shares of Repligen during the third quarter worth about $29,000. Bayforest Capital Ltd purchased a new position in Repligen in the 4th quarter worth approximately $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen in the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC purchased a new stake in Repligen during the 4th quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC grew its holdings in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.